- XIPERE is referred to as Arcatus (ARVN001) by Arctic Vision “ ALPHARETTA, Ga., July 10, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company...
SHANGHAI, July 4, 2022 /PRNewswire/ -- Arctic Vision, a China-based biotech company focused on innovative ophthalmic therapies, today announced that the first patient has been enrolled in a Phase III clinical study evaluating ARVN003, a proprietary pilocarpine formulation leveraging its micro dosing platform Optejet®, as a treatment to temporarily improve vision in adults with presbyopia in China.
SHANGHAI, Nov. 22, 2021 /PRNewswire/ -- Arctic Vision, a China-based biotech company focused on innovative ophthalmic therapies, announced on Nov. 19 that the first set of patients have been dosed in the Phase III study of ARVN001 (triamcinolone acetonide suprachoroidal injectable suspension, known as XIPERE™ in the U.S.) for the treatment of macular edema associated with uveitis (UME) in China. ARVN001 is a first-in-class investigational therapy directly targeting the suprachoroidal space (SCS®). In the U.S., the New Drug Application (NDA) for XIPERE™ for UME treatment was approved by the U.S. Food and Drug Administration (FDA) on Oct 25, 2021, and the product is expected to be launched soon.
SHANGHAI, Sept. 16, 2021 /PRNewswire/ -- Arctic Vision, a China-based biotech company focused on innovative ophthalmic therapies, announced today that it will expand its exclusive license agreement with Eyenovia, Inc. (NASDAQ: EYEN) to include a third asset, MydCombi™, for development and commercialization in Greater China (mainland China, Hong Kong, Macau and Taiwan) and South Korea.
ALPHARETTA, Ga., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today it has agreed to expand the territories covered by its exclusive license agreement with Arctic Vision, a China-based biotech company focused on innovative ophthalmic therapies. As now amended, the licensed territory for XIPERE™ (triamcinolone acetonide suprachoroidal injectable suspension) has been expanded from Greater China (mainland China, Hong Kong, Macau and Taiwan) and South Korea to also include Australia, New Zealand, India and the ASEAN Countries (Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, Singapore, Thailand, and Vietnam).
Arctic Vision, a China-based ophthalmic biotech focusing on breakthrough therapies, with a leading portfolio covering pre-clinical stage to commercial stage products, announced the clearance of the Investigational New Drug (IND) application for phase III study of ARVN003 (pilocarpine microdose ophthalmic solution) for the treatment of presbyopia by the Center for Drug Evaluation, China National Medical Products Administration (CDE, NMPA). It is the first clinical trial approved in China for presbyopia treatment.
Arctic Vision, a China-based biotech company focused on innovative ophthalmic therapies, announced the entering of an amendment to the exclusive license agreement with its partner Clearside Biomedical, Inc. (Clearside), to expand the licensed territory for ARVN001 (triamcinolone acetonide suprachoroidal injectable suspension, known as Xipere in the US) from Greater China (mainland China, Hong Kong, Macau and Taiwan) and South Korea to also include ASEAN Countries (Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, Singapore, Thailand, and Vietnam) and India.
Arctic Vision, a China-based clinical-stage ophthalmology company, announced new research collaboration with Prof. Christopher Leung, Head and Clinical Professor at the Department of Ophthalmology of the University of Hong Kong (HKU) for the discovery and development of novel neuroprotective therapies for glaucoma.
Arctic Vision and ActualEyes, a clinical stage Japanese biotech company committed to the research and development of cell therapy for corneal endothelial diseases, jointly announced an exclusive licensing agreement for Arctic Vision to develop and commercialize ActualEyes’ lead product candidate, AE-101, for the treatment of corneal endothelial dysfunction in Greater China (mainland China, Hong Kong, Macau and Taiwan) and South Korea.